Browse > Article
http://dx.doi.org/10.7314/APJCP.2016.17.9.4483

Does Human Epididymis Protein 4 (HE4) Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer  

Innao, Pedrada (Department of Obstetrics and Gynecology Sunprasittiprasong hospital Ubonratchathani)
Pothisuwan, Methasinee (Department of Obstetrics and Gynecology Sunprasittiprasong hospital Ubonratchathani)
Pengsa, Prasit (Department of Obstetrics and Gynecology Sunprasittiprasong hospital Ubonratchathani)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.9, 2016 , pp. 4483-4486 More about this Journal
Abstract
Background: Despite the fact that ovarian cancer is the seventh most common cancer in women worldwide and the fifth leading cause of cancer death, It is the most common cause of death due to reproductive cancers in Thailand where epithelial ovarian cancer (EOC) is commonly found. According to a Thai statistical analysis in 2010 by the Department of Medical Services, epithelial ovarian cancer was the sixth most common cancer in Thailand from 2001to 2003.The incidence of 5.1 per 100,000 women per year. Human epididymis protein 4 (HE4) is a novo diagnostic tumor marker for EOC. The combination of HE4 and carcinoma antigen 125 (CA 125) is a tool for detecting epithelial ovarian cancer (EOC) better than using CA 125 alone. Therefore, the researcher is interested in HE4 does have a role to predict recurrent epithelial ovarian cancer. Materials and Methods: The patients who had complete response after diagnosed with epithelial ovarian cancer by pathology, FIGO stage 3 or more had been treated through surgery and chemotherapy at the Sunpasitthiprasong Hospital from June 2014 until March 2016. The patients were followed up every three months, using tumor marker (CA 125, HE4,Carcinoma antigen 19-9) together with other checkup methods, such as rectovaginal examination, CXR every year and other imaging as indication. Afterwards, the data was analyzed for the ability of HE4 to detect recurrence of epithelial ovarian cancer. Results: In 47 patients in this study follow-up for 22 months after complete response treatment from surgery and chemotherapy in epithelial ovarian cancer, 23 had recurrent disease and HE4 titer rising. The patients with recurrent epithelial ovarian cancer demonstrated high levels of both HE4 and CA125 with sensitivity of 91.3% and 52.7% respectively, specificity of 87.5% and 95.6% and positive predictive values of 87.5% and 85.7%. HE4 can predict recurrent epithelial ovarian cancer (p-value=0.02242). Comparing HE4 and CA125 in predicting recurrent epithelial ovarian cancer HE4 had more potential than CA125 (p-value =0.8314). Conclusions: The present study showed HE4 to have a role in predicting recurrent epithelial ovarian cancer and HE4 is potentially better than CA125 as a marker for this purpose.
Keywords
Epithelial ovarian cancer; recurrence; tumor marker; human epididymis protein 4;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Anastasi E, Marchei GG (2010). HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumor Biol, 31, 113-9.   DOI
2 Berek SJ, Natarajan S (2007). Ovarian and fallopian tube cancer. In: Berek JS, editor.
3 Berek& Novak's gynecology. 14th ed. Philadelphia: Lippincott Williams& Wilkins, 1457-547.
4 Drapkin R, von Horsten HH, Lin Y, et al (2005). Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 65, 2162-9   DOI
5 Drapkin R, von Horsten HH, Lin Yet al (2005). Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 65, 2162-9   DOI
6 Govindan R,Devita A, Hellman B et al (2012). Principles and Practice of Oncology. 3 rd edition, 1586.
7 Imsamran W, Chaiwerawattana A, Wiangnon S, et al (2015). Cancer in Thailand, 3, 55.
8 Li J, Dowdy S, Tipton T et al (2009). HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn, 9, 555-66.   DOI
9 Moore RG, Brown AK (2008). The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecooocol, 2, 402-8.
10 Narakorn C (2011). Epithelial ovarian cancer. In:Srisomboon J , Wilailak S,Narakorn C et al, editor, Gynecologic oncology. Bangkok, Pimdee, 199-243.
11 Plotti F, Capriglione S (2012). Does HE4 have a role as biomarker in the recurrence of ovarian cancer. Int Society Oncol Biomarkers, 33, 2117-23
12 Trudel D (2010). Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Int Society Oncol Biomarkers, 31, 113-119
13 United States Cancer Statistics: 1999-2013 (2016). Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health And Human Services, Centers for Disease Control and Prevention, and National Cancer Institute.
14 Wilailak S, Khuhaprema T, Srivatanakul P, et al (2009). Epidemiologic report of gynecologic cancer in Thailand. J Gynecol Oncol, 20, 81-3.   DOI